Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 19/20 | 0.76 |
| ▸ | KDR | P35968 | 19/20 | 0.76 |
| ▸ | FLT1 | P17948 | 2/20 | 0.75 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.75 |
| ▸ | FLT4 | P35916 | 2/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | STK10 | O94804 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
| ▸ | LYN | P07948 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 1/20 | 0.75 |
| ▸ | MET | P08581 | 1/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.75 |
| ▸ | KIT | P10721 | 1/20 | 0.75 |
| ▸ | BCR | P11274 | 1/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.75 |
| ▸ | HTR2A | P28223 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21174284 | 0.99 | PDGFRA (0.74) | PDGFRAKDRFLT1EPHB2FLT4 | |
| SCHEMBL1873986 | 0.96 | PDGFRA (0.70) | PDGFRAKDRFLT1EPHB2FLT4 | |
| SCHEMBL29973354 | 0.89 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL27081475 | 0.89 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL21174250 | 0.89 | PDGFRA (0.73) | PDGFRAKDR | |
| SCHEMBL6376965 | 0.87 | FLT3 (0.79) | PDGFRAKDRFLT1EPHB2FLT4 | |
| SCHEMBL3931065 | 0.86 | PDGFRA (1.00) | PDGFRAKDR | |
| SCHEMBL5651032 | 0.86 | KDR (0.81) | PDGFRAKDRFLT1EPHB2FLT4 | |
| Tivozanib SCHEMBL172883 | 0.86 | KDR (1.00) | PDGFRAKDRFLT1EPHB2FLT4 | |
| Hydrochloric Acid SCHEMBL5653983 | 0.86 | FLT3 (0.78) | PDGFRAKDRFLT1EPHB2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | NR1H2, NR1H3, NR1H4 | PDGFRA 1364/4885KDR 1874/4885FLT1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.